Welcome to our dedicated page for Bristol-Myers Squibb news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb stock.
Bristol Myers Squibb reports news on its pharmaceutical portfolio across oncology, cardiovascular disease and immunology, including regulatory decisions, clinical trial data, commercial access programs and product collaborations. Company updates include Sotyktu (deucravacitinib), a selective TYK2 inhibitor approved in the European Union for active psoriatic arthritis, and Eliquis (apixaban), an oral anticoagulant marketed through the Bristol Myers Squibb-Pfizer alliance.
Recurring developments also cover quarterly financial results, investor conference participation, debt and capital-market activity, research collaborations in cardiovascular and precision-medicine programs, and community initiatives tied to multiple myeloma care. The company’s news flow combines product-specific regulatory milestones with broader disclosures on operating performance and pipeline partnerships.
Bristol Myers Squibb announced that the FDA has approved Opdualag, a fixed-dose dual immunotherapy combining nivolumab and relatlimab, for patients aged 12 and older with unresectable or metastatic melanoma. This innovative treatment showed a median progression-free survival of 10.1 months, more than doubling the 4.6 months seen with nivolumab alone in the RELATIVITY-047 trial. The safety profile is consistent with nivolumab, with 14.6% of patients experiencing drug-related adverse events leading to discontinuation. This marks a significant expansion of treatment options for melanoma patients.
Bristol Myers Squibb (NYSE: BMY) and Nektar Therapeutics (NASDAQ: NKTR) reported disappointing results from the Phase 3 PIVOT IO-001 study evaluating bempegaldesleukin plus Opdivo versus Opdivo alone in metastatic melanoma. The independent Data Monitoring Committee found no significant benefits in progression-free survival (PFS) or objective response rate (ORR). Consequently, the companies decided to unblind the trial and halt enrollment for the related PIVOT-12 study. The focus will now shift to ongoing studies in renal cell carcinoma and bladder cancer.
Bristol Myers Squibb (NYSE:BMY) will report its first quarter 2022 financial results on April 29, 2022. The company will host a conference call at 8:00 a.m. ET the same day to discuss these results and answer questions from analysts and investors. The call will be accessible via webcast at investor.bms.com. A replay will be available three hours post-call, and live access will be provided through U.S. toll-free and international numbers.
Bristol Myers Squibb (NYSE: BMY) announced its participation in investor conferences on March 16, 2022. Rupert Vessey, Executive VP, will engage in a fireside chat at the Guggenheim Healthcare Talks at 10:15 a.m. ET. Samit Hirawat, Chief Medical Officer, will also participate at the Barclays’ Global Healthcare Conference in location value="LU/us.fl.miami"Miami, Florida at 1:35 p.m. ET. Live webcasts of both sessions will be available at investor.bms.com.
Bristol Myers Squibb (NYSE: BMY) announced FDA approval for Opdivo® (nivolumab) in combination with platinum-doublet chemotherapy as the first immunotherapy-based treatment for resectable non-small cell lung cancer (NSCLC) in the neoadjuvant setting. This approval follows the Phase 3 CheckMate -816 trial, demonstrating a 37% reduction in progression risk and a median event-free survival of 31.6 months with Opdivo, compared to 20.8 months for chemotherapy alone. The approval enhances treatment options prior to surgery, regardless of PD-L1 status.
Bristol-Myers Squibb Company (NYSE:BMY) announced the accepted amounts and pricing for their 22 separate cash offers to purchase notes. Key details include:
- Majority of 2025 and 2026 Pool Notes accepted with yields of 1.961% and 1.842% respectively.
- A total principal amount of $1.6 billion accepted from the 2029 Pool Notes with a yield of 2.356%.
- The Offers are set to expire on March 15, 2022, unless extended.
All accepted Notes will be cancelled, with the Early Settlement Date occurring on March 4, 2022.
Bristol-Myers Squibb (NYSE: BMY) announced early results for its tender offers, with a new maximum purchase price up to $4 billion for multiple series of notes. As of March 1, 2022, significant tendering was reported, including $821.88 million for 2025 notes and $1.45 billion for 2026 notes. The offers include various pools, such as 2025, 2026, and high coupon notes. The deadline for acceptance is set for March 15, 2022. The company will issue a press release on March 2, 2022, detailing the accepted amounts and yields.
Bristol Myers Squibb (NYSE: BMY) has declared a quarterly dividend of $0.54 per share on its common stock, payable on May 2, 2022, to stockholders of record by April 1, 2022. Additionally, a quarterly dividend of $0.50 per share on its convertible preferred stock will be paid on June 1, 2022, with a record date of May 10, 2022. This consistent dividend policy reflects confidence in the company’s ongoing financial health and commitment to returning value to shareholders.
Dragonfly Therapeutics has achieved a significant milestone in its Phase 1 clinical trial for the DF6002/BMS-9896415 IL-12 program, receiving a milestone payment from Bristol Myers Squibb (BMY). DF6002, an investigational monovalent IL-12 immunoglobulin Fc fusion protein, aims to enhance anti-tumor responses in patients with advanced solid tumors. The trial, which began in July 2020, focuses on assessing the safety and anti-tumor activity of DF6002. With Bristol Myers Squibb responsible for development and commercialization, Dragonfly stands to gain further milestone payments and royalties on net sales.
Bristol Myers Squibb has announced the FDA's acceptance of its supplemental Biologics License Application for Opdivo plus chemotherapy, targeting resectable non-small cell lung cancer (NSCLC). This application, based on the CheckMate -816 trial results, has received Priority Review status, with a PDUFA goal date set for July 13, 2022. The CheckMate -816 trial indicated significant improvements in pathologic complete response and event-free survival when compared to chemotherapy alone. If approved, this would be the first immunotherapy-based neoadjuvant treatment option for NSCLC in the U.S., addressing a critical need in early-stage lung cancer treatment.